Key result
Novel apolipoproteins and lysophospholipids critically modulate vascular inflammation and atherosclerosis beyond classical cholesterol.
Why the study?
Traditional management of atherosclerosis focuses primarily on cholesterol and triglycerides, yet lipoproteins also transport bioactive lipids and apolipoproteins that critically regulate systemic inflammation and metabolic health beyond classical lipid accumulation.
This review highlights the mechanistic crosstalk between lipid transporters, apolipoproteins (such as ApoM and ApoD), and bioactive lysophospholipids (such as S1P and LPA) in regulating systemic inflammation, glucose metabolism, and atherosclerosis beyond classical cholesterol and triglyceride accumulation.
Answers are grounded in this paper and cite their sources.
May highlight new atherosclerosis biomarkers; extends mechanistic insights beyond cholesterol but leaves clinical adoption open.
Traditional management of atherosclerosis focuses primarily on cholesterol and triglycerides; however, lipoproteins also transport bioactive lipids that critically regulate systemic inflammation and metabolic health. This review highlights the diverse physiological and clinical roles of apolipoproteins and bioactive lipids beyond classical lipid accumulation. First, we discuss how hepatic transporters NPC1L1 and ABCG5/8 modulate glucose metabolism and handle non-cholesterol lipids, including phytosterols. Second, we emphasize the apolipoprotein M (ApoM) and sphingosine 1-phosphate (S1P) axis. ApoM protects S1P from degradation and directly mediates the pleiotropic benefits of high-density lipoprotein (HDL), including anti-apoptotic, antithrombotic, and renoprotective effects. Third, reverse translational research utilizing genome-wide association studies identifies apolipoprotein D (ApoD) as a key anti-inflammatory modulator. Finally, clinical lipidomics underscores the importance of "minor" lysophospholipids, such as lysophosphatidylinositol and lysophosphatidylserine, alongside lysophosphatidic acid in the pathogenesis of acute coronary syndrome. Understanding the dynamic crosstalk between lipid transporters, apolipoproteins, and bioactive lipids provides novel mechanistic insights into cardiovascular and metabolic diseases, paving the way for innovative biomarkers and precision therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Makoto Kurano (2026) conducted a review in Atherosclerosis and metabolic diseases. Lipoproteins, apolipoproteins (ApoM, ApoD), and bioactive lipids (S1P, lysophospholipids) was evaluated. Apolipoproteins (ApoM, ApoD) and bioactive lysophospholipids (S1P, LPA, LPI, LysoPS) critically modulate vascular inflammation, glucose homeostasis, and atherosclerosis beyond classical cholesterol.
Synapse has enriched 10 related papers. Consider them for comparative context: